Cargando…

Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma

Checkpoint kinase 1 (CHK1) is an integral component of the cell cycle as well as the DNA Damage Response (DDR) pathway. Previous work has demonstrated the effectiveness of inhibiting CHK1 with small-molecule inhibitors, but the role of CHK1 mediated DDR in medulloblastoma is unknown. CHK1, both at t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prince, Eric W., Balakrishnan, Ilango, Shah, Monil, Mulcahy Levy, Jean M., Griesinger, Andrea M., Alimova, Irina, Harris, Peter S., Birks, Diane K., Donson, Andrew M., Davidson, Nathan, Remke, Marc, Taylor, Michael D., Handler, Michael H., Foreman, Nicholas K., Venkataraman, Sujatha, Vibhakar, Rajeev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288228/ https://www.ncbi.nlm.nih.gov/pubmed/27449089 http://dx.doi.org/10.18632/oncotarget.10692

Ejemplares similares

Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma
por: Venkataraman, Sujatha, et al.
Publicado: (2014)

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma
por: Harris, Peter S, et al.
Publicado: (2014)

Polo-like Kinase 1 as a potential therapeutic target in Diffuse Intrinsic Pontine Glioma
por: Amani, Vladimir, et al.
Publicado: (2016)

MPS1 kinase as a potential therapeutic target in medulloblastoma
por: Alimova, Irina, et al.
Publicado: (2016)

Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells
por: Harris, Peter S, et al.
Publicado: (2012)

MEDB-44. Transcriptomic resolution of subgroup-specific medulloblastoma architecture
por: Willard, Nicholas, et al.
Publicado: (2022)

Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor
por: Alimova, Irina, et al.
Publicado: (2017)

MEDB-28. CDK9 is a druggable mediator sustaining Myc-driven circuitry in medulloblastoma
por: Madhavan, Krishna, et al.
Publicado: (2022)

MBRS-65. FBXW7 ACTS A TUMOR SUPPRESSOR IN MYC-DRIVEN MEDULLOBLASTOMA BY CONTROLLING A FEED-FORWARD REGULATORY LOOP OF PLK1 AND MYC
por: Wang, Dong, et al.
Publicado: (2020)

A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma
por: Wang, Dong, et al.
Publicado: (2021)

MEDB-70. Metabolism mediated radiation resistance in MYC-driven Medulloblastoma
por: Veo, Bethany, et al.
Publicado: (2022)

MDB-37. CDK9 IS A DRUGGABLE MEDIATOR SUSTAINING MYC-DRIVEN TRANSCRIPTIONAL CIRCUITRY IN MEDULLOBLASTOMA
por: Krishna, Madhavan, et al.
Publicado: (2023)

MBRS-67. ROLE OF CYCLIN DEPENDENT KINASE-9 IN Myc-ENHANCED MEDULLOBLASTOMA
por: Madhavan, Krishna, et al.
Publicado: (2020)

MBRS-46. CHARTING NEOPLASTIC AND IMMUNE CELL HETEROGENEITY IN HUMAN AND GEM MODELS OF MEDULLOBLASTOMA USING scRNAseq
por: Donson, Andrew, et al.
Publicado: (2020)

MicroRNA 128a Increases Intracellular ROS Level by Targeting Bmi-1 and Inhibits Medulloblastoma Cancer Cell Growth by Promoting Senescence
por: Venkataraman, Sujatha, et al.
Publicado: (2010)

MBRS-71. ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN ATTENUATES DNA DAMAGE AND IS A THERAPEUTIC TARGET IN Myc-DRIVEN MEDULLOBLASTOMA
por: Abdel-Hafiz, Ahmed, et al.
Publicado: (2020)

MEDB-80. CDK8 promotes stemness of MYC-driven medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors
por: Alimova, Irina, et al.
Publicado: (2022)

MEDB-81. Combined inhibition of CDK11 and EZH2 results in regression of MYC-amplified medulloblastoma
por: Wang, Dong, et al.
Publicado: (2022)

EPEN-31. SINGLE-CELL RNAseq OF CHILDHOOD EPENDYMOMA REVEALS DISTINCT NEOPLASTIC CELL SUBPOPULATIONS THAT IMPACT ETIOLOGY, MOLECULAR CLASSIFICATION AND OUTCOME
por: Donson, Andrew, et al.
Publicado: (2020)

EMBR-27. NEOPLASTIC AND IMMUNE SINGLE CELL TRANSCRIPTOMICS DEFINE SUBGROUP-SPECIFIC INTRA-TUMORAL HETEROGENEITY OF CHILDHOOD MEDULLOBLASTOMA
por: Donson, Andrew, et al.
Publicado: (2021)

Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis
por: Purvis, Ian J., et al.
Publicado: (2019)

XRT-02. SINGLE-CELL RNA SEQUENCING IDENTIFIES FUNCTIONAL MACROPHAGE SUBSETS THAT ARE ENRICHED IN RESPONSE TO DIFFERENTIAL PHAGOCYTOSIS INDUCTION AGAINST GLIOMA
por: Lakshmanachetty, Senthilnath, et al.
Publicado: (2023)

ATRT-23. SIRT2 cooperates with SMARCB1 to induce a differentiation block in ATRT
por: Alimova, Irina, et al.
Publicado: (2022)

ATRT-06. SMARCB1 LOSS DRIVEN NON-CANONICAL PRC1 ACTIVITY REGULATES DIFFERENTIATION IN ATYPICAL TERATOID RHABDOID TUMORS (ATRT)
por: Alimova, Irina, et al.
Publicado: (2020)

Combined EphB2 receptor knockdown with radiation decreases cell viability and invasion in medulloblastoma
por: Bhatia, Shilpa, et al.
Publicado: (2017)

HGG-18. SINGLE CELL RNA-SEQ ANALYSIS OF PEDIATRIC HIGH-GRADE GLIOMA PATIENT SAMPLES IDENTIFIES COMMON GLIAL AND IMMUNE CELL TYPES THAT HELP TO EXPLAIN HETEROGENEITY AND TUMORIGENESIS
por: DeSisto, John, et al.
Publicado: (2023)

MBRS-26. CDK7 MEDIATED TRANSCRIPTIONAL PROCESSIVITY OF DNA REPAIR NETWORKS REGULATES SENSITIVITY TO RADIATION IN MYC DRIVEN MEDULLOBLASTOMA
por: Veo, Bethany, et al.
Publicado: (2020)

DIPG-73. SENESCENCE ASSOCIATED SECRETORY PHENOTYPE AS A MECHANISM OF RESISTANCE AND THERAPEUTIC VULNERABILITY IN BMI1 INHIBITOR TREATED DIPG
por: Balakrishnan, Ilango, et al.
Publicado: (2020)

EPEN-26. NON-CANONICAL NF-κB SIGNALING DRIVES MESENCHYMAL EPENDYMAL CELL SUBPOPULATION IN PFA EPENDYMOMA
por: Griesinger, Andrea, et al.
Publicado: (2020)

HGG-25. PRMT5 PROMOTES TUMOR GROWTH BY MAINTAINING STEMNESS OF PEDIATRIC HIGH-GRADE GLIOMA CELLS
por: DeSisto, John, et al.
Publicado: (2021)

IMG-17. RADIOMICS CHARACTERIZATION OF FOUR PEDIATRIC BRAIN TUMOR SUBTYPES IN PDX MOUSE MODELS
por: Serkova, Natalie, et al.
Publicado: (2020)

IMMU-07. TACEDINALINE (CI994), A CLASS I HDAC INHIBITOR, TARGETS INTRINSIC TUMOR GROWTH AND LEPTOMENINGEAL DISSEMINATION IN MYC-DRIVEN MEDULLOBLASTOMA WHILE MAKING THEM SUSCEPTIBLE TO ANTI-CD47 INDUCED MACROPHAGE PHAGOCYTOSIS VIA NF-KB-TGM2 DRIVEN TUMOR INFLAMMATION
por: Marquardt, Viktoria, et al.
Publicado: (2023)

HGG-20. PRMT5 promotes the formation and growth of pediatric high-grade glioma by maintaining tumor stem cell populations
por: DeSisto, John, et al.
Publicado: (2022)

Preclinical analysis of MTOR complex 1/2 inhibition in diffuse intrinsic pontine glioma
por: Flannery, Patrick C., et al.
Publicado: (2018)

Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
por: Balakrishnan, Ilango, et al.
Publicado: (2020)

DIPG-34. SUPER ELONGATION COMPLEX AS A TARGETABLE DEPENDENCY IN H3K27M+ DIFFUSE MIDLINE GLIOMA
por: Dahl, Nathan, et al.
Publicado: (2020)

DIPG-56. Development and application of a novel antibody against CD99 as a therapeutic strategy in Diffuse Midline Glioma
por: Venkataraman, Sujatha, et al.
Publicado: (2022)

Unique Molecular Characteristics of Pediatric Myxopapillary Ependymoma
por: Barton, Valerie N., et al.
Publicado: (2009)

HGG-12. Rapid PTEFb-dependent transcriptional reorganization underpins the glioma adaptive response to radiotherapy
por: Walker, Faye, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tmeh7oc407a29avf4qmivchbvl